Sherman, Scott K <br/><br/>
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.  [electronic resource] 

 -  JAMA oncology  02 2019 
 - 236-242 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2018.5070  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab--administration & dosage<br/>Capecitabine--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Drug Costs<br/>Female<br/>Humans<br/>Maintenance Chemotherapy--economics<br/>Male<br/>Markov Chains<br/>Medicare--economics<br/>Middle Aged<br/>Models, Economic<br/>Neoplasm Metastasis<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Time Factors<br/>Treatment Outcome<br/>United States